Cerenome, Inc. CNSY
Cerenome, Inc. (Nasdaq: CNSY) is an oncology drug developer. Its lead program, rhenium (186Re) obisbemeda (REYOBIQ), is in Phase 2 for recurrent glioblastoma; leptomeningeal metastases; pediatric brain cancers. Its next catalyst on record is obisbemeda ReSPECT-PBC: First patient enrolled in Phase 1 pediatric trial (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: obisbemeda ReSPECT-PBC — First patient enrolled in Phase 1 pediatric trial (H2 2026). 11 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| rhenium (186Re) obisbemeda - ReSPECT-GBM | recurrent glioblastoma | radiopharmaceutical | Phase 2 |
| rhenium (186Re) obisbemeda - ReSPECT-LM multi-dose | leptomeningeal metastases | radiopharmaceutical | Phase 2 |
| rhenium (186Re) obisbemeda - ReSPECT-PBC | pediatric brain cancer (HGG, ependymoma) | radiopharmaceutical | Pre-clinical |
| 188RNL-BAM | liver and other solid organ cancers | device-combination | Pre-clinical |
Recent results and decisions
- Oct 2, 2026positive REYOBIQ achieved median overall survival of 13 months and median progression-free survival of 11 months in 15 patients with recurrent glioblastoma in Phase 2 interim analysis.
Median overall survival (mOS) in 15 patients from Phase 2 study was 13 months, 63% better than current standard of care (8 months) Median progression free survival (mPFS) 11 months, vs. SOC at 4 months
Filing - Oct 2, 2026approval Medicare reimbursement rate for CNSide diagnostic platform expected effective January 1, 2027.
Medicare Rate Effective (pending) Rate effective Jan 1, 2027
Filing - Oct 2, 2026positive ReSPECT-LM Phase 1a single-dose trial (N=29) completed, establishing RP2D of 44.1 mCi with 87% clinical response rate (CR+PR+SD) and 9-month median overall survival.
Clinical Response (CR+PR+SD) 87% 13 of 15 patients Median Overall Survival 9 months N = 16 patients Clinical Benefit 44.1 mCi RP2D established 2 of 29 Patients with dose limiting toxicity
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.